

P1748

Poster Session VI

Molecular diagnosis of sexually-transmitted pathogens

A NOVEL MOLECULAR-BASED DIAGNOSTIC SCREENING TEST UTILIZING THE NANOCHIP® MICROARRAY TECHNOLOGY FOR SIMULTANEOUS DETECTION OF MAJOR SEXUALLY TRANSMITTED INFECTIONS

Z. Greenberg¹, M. Fridlender¹, R. Sabban-Amin¹, Y. Mali¹, J. Kopelowitz¹

¹Research & Development, Savyon Diagnostics Ltd., Ashdod, Israel

Objectives. Sexually transmitted infections (STI) are widely abundant all over the world, presenting constantly a yearly growing trend and consequently increased annual health costs. STIs may cause acute symptoms, chronic infections, infertility, ectopic pregnancy, blindness, cervical cancer, susceptibility to HIV infection and death. Most cases are treatable, however no or late treatment may lead to severe health complications. This is further emphasized in view of the common carriage of STIs in asymptomatic state. Therefore, there is a need for detection of early stages of STIs in order to control and prevent these diseases. Savyon Diagnostics has recently been engaged with development of a novel molecular-based screening test for simultaneous detection of the most abundant STIs utilizing its proprietary NanoCHIP®XL molecular electronic microarray system. The panel of pathogens is composed of *Chlamydia trachomatis*, *Neisseria gonorrhoea*, *Trichomonas vaginalis*, *Ureaplasma urealyticum/parvum*, *Mycoplasma genitalium* and *Mycoplasma hominis*. The *Ureaplasma urealyticum/parvum* results are reported in a semi-quantitative manner, in order to better differentiate between colonization and acute states, and by that avoiding unnecessary antibiotic treatment. The aim of this work is to demonstrate the utility of the newly developed test for screening purposes of STIs especially in high-risk populations, demonstrating a highly performing, time-saving and cost-effective test.

Methods. DNA was extracted from characterized urethral samples or urine swab specimens using a variety of readily available manual and automatic methods. Specific bacterial and parasitic genes were amplified through multiplex PCR and subjected to the NanoCHIP® detection and analysis system. The generated amplicons were electronically addressed to discrete loci on the NanoCHIP® cartridge, pre-activated with specific capture oligonucleotides. Detection was achieved through specific fluorescent reporter oligonucleotides. The molecular method used in the testing laboratory, and STD6 ACE Detection kit of Seegene were used as reference methods.

Results. The NanoCHIP® results were in accordance with the characterizations of the tested samples in terms of clinical sensitivity and specificity. The NanoCHIP® multiplex analysis provided clear results about the identity of the pathogen, either bacterium or parasite, within a working day time frame.

Conclusions. The NanoCHIP® based test has proven to be a useful system for medium-high throughput screening of urine and swab samples for reliable detection of STIs. The NanoCHIP® technology presents significant advantages, mainly in terms of minimal hands-on time, improved laboratory workflow and turnaround time, enabling flexibility and saving costs.